Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | PLAU | P00749 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | PREP | P48147 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27040991 | 0.89 | CHRM2 (0.48) | ALDH1A1LMNAMAPTGPR119CHRM2 | |
| SCHEMBL27040994 | 0.89 | CHRM2 (0.48) | ALDH1A1LMNAMAPTGPR119CHRM2 | |
| SCHEMBL15728634 | 0.89 | CHRM2 (0.48) | ALDH1A1LMNAMAPTGPR119CHRM2 | |
| SCHEMBL30955751 | 0.85 | GPR119 (0.41) | ALDH1A1LMNAMAPTGAACYP2C9 | |
| SCHEMBL30955761 | 0.85 | GPR119 (0.41) | ALDH1A1LMNAMAPTGAACYP2C9 | |
| SCHEMBL16423801 | 0.82 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPTGAACYP2C9 | |
| SCHEMBL18383164 | 0.81 | LMNA (0.42) | ALDH1A1LMNAMAPTGAACYP2C9 | |
| SCHEMBL18383167 | 0.81 | LMNA (0.42) | ALDH1A1LMNAMAPTGAACYP2C9 | |
| SCHEMBL22587586 | 0.81 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTGPR119DDB1 | |
| SCHEMBL17187785 | 0.81 | CHRM2 (0.40) | GPR119CHRM2CHRM1CHRM3DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135836-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-10280184-B2 | Heterocyclic kinase inhibitors | ABBVIE INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20170114077-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114077-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114077-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC. | 2017-04-27 | — | — | US | disclosed |
| WO-2015158283-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC. (US) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280184-B2 | Heterocyclic kinase inhibitors | MAP3K1, MAP3K20, MAP3K19 | ALDH1A1 1550/4885LMNA 2236/4885MAPT 3679/4885 |
| US-20170114077-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K19 | ALDH1A1 1550/4885LMNA 2236/4885MAPT 3679/4885 |
| US-20190135836-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K19 | ALDH1A1 1582/4885LMNA 2324/4885MAPT 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.